trending Market Intelligence /marketintelligence/en/news-insights/trending/MXoZU05b__7RODpx5k0slg2 content esgSubNav
In This List

Inovio's Zika vaccine invokes response in first human study

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Inovio's Zika vaccine invokes response in first human study

Inovio Pharmaceuticals Inc.'s DNA-based Zika vaccine, GLS-5700, invoked an immune response and was considered to have a positive safety profile in its first human study.

Inovio had previously released data indicating that the vaccine protected animals from the infection.

In the phase 1 clinical trial, known as ZIKA-001, the vaccine induced high levels of binding antibodies in 100% of participants.

"Results from this published study demonstrate that all human subjects responded to the vaccine and that the immune responses have the ability to confer protection in challenge models. A second phase 1 study, now fully enrolled in Puerto Rico, is designed with a placebo control to explore a potential trend towards clinical efficacy," Inovio President and CEO J. Joseph Kim said in a statement.

Inovio is developing GLS-5700 in collaboration with GeneOne Life Science Inc. and The Wistar Institute.

It is also studying the vaccine for dengue virus-positive individuals.